MA54222A - Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées - Google Patents

Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées

Info

Publication number
MA54222A
MA54222A MA054222A MA54222A MA54222A MA 54222 A MA54222 A MA 54222A MA 054222 A MA054222 A MA 054222A MA 54222 A MA54222 A MA 54222A MA 54222 A MA54222 A MA 54222A
Authority
MA
Morocco
Prior art keywords
midostaurin
mcl
inhibitor
combination
pharmaceutical compositions
Prior art date
Application number
MA054222A
Other languages
English (en)
Inventor
Ensar Halilovic
Marina Konopleva
Erick Morris
Anna Skwarska
Youzhen Wang
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of MA54222A publication Critical patent/MA54222A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA054222A 2018-11-14 2019-11-14 Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées MA54222A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767007P 2018-11-14 2018-11-14
US201962824515P 2019-03-27 2019-03-27
US201962912160P 2019-10-08 2019-10-08

Publications (1)

Publication Number Publication Date
MA54222A true MA54222A (fr) 2021-09-22

Family

ID=68696369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054222A MA54222A (fr) 2018-11-14 2019-11-14 Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées

Country Status (13)

Country Link
US (1) US20220016118A1 (fr)
EP (1) EP3880207B1 (fr)
JP (1) JP7493503B2 (fr)
KR (1) KR20210091758A (fr)
CN (1) CN113382732A (fr)
AU (1) AU2019379782A1 (fr)
BR (1) BR112021009050A2 (fr)
ES (1) ES2978336T3 (fr)
IL (1) IL283105A (fr)
MA (1) MA54222A (fr)
MX (1) MX2021005681A (fr)
TW (1) TWI849001B (fr)
WO (1) WO2020099542A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222752A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugues anti-corps-medicament
EP4351564A1 (fr) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37459A (es) 2016-10-28 2018-05-31 Servier Lab Formulación liposomal
EP3567043B1 (fr) * 2017-01-05 2023-12-06 Henan Genuine Biotech Co., Ltd. Dérivés du acide propanoïque 2-[[5-[(4-hydroxy-3-chloro-2-méthyl)-phényl]-thiéno[2,3-d]pyrimidin-4-yl]oxy]-3-(2-méthoxybenzene) en tant qu'inhibiteurs mcl-1 et bcl-2 pour le traitement du cancer

Also Published As

Publication number Publication date
JP7493503B2 (ja) 2024-05-31
EP3880207A1 (fr) 2021-09-22
CN113382732A (zh) 2021-09-10
IL283105A (en) 2021-06-30
AU2019379782A1 (en) 2021-06-10
WO2020099542A1 (fr) 2020-05-22
BR112021009050A2 (pt) 2021-08-10
EP3880207B1 (fr) 2024-03-27
ES2978336T3 (es) 2024-09-10
TWI849001B (zh) 2024-07-21
US20220016118A1 (en) 2022-01-20
CA3119395A1 (fr) 2020-05-22
JP2022507260A (ja) 2022-01-18
MX2021005681A (es) 2021-09-21
TW202038960A (zh) 2020-11-01
KR20210091758A (ko) 2021-07-22

Similar Documents

Publication Publication Date Title
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
EP3778608A4 (fr) Dérivés de carbamoylpyridone polycycliques, compositions pharmaceutiques et utilisation de ceux-ci
EP3687543A4 (fr) Agents pharmaceutiques en combinaison en tant qu'inhibiteurs de rsv
MX2020005063A (es) Inhibidores de kras g12c.
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
EP3904351A4 (fr) Inhibiteur de fak et combinaison de médicaments associée
EP3843704A4 (fr) Formulations d'émulsion d'inhibiteurs de multikinase
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
EP3737665A4 (fr) Promédicaments à base de kétamine, compositions et utilisations de ceux-ci
MA51066A (fr) Inhibiteurs d'intégrine
EP3407976A4 (fr) Compositions et utilisations d'agents alpha-adrénergiques
EP3723752A4 (fr) Nouvelles formes solides de cannabidiol et utilisations associées
MA47743A (fr) Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EP3846807A4 (fr) Composés d'imidazoquinoléine et leurs utilisations
EP3876935A4 (fr) FORMULATIONS TOPIQUES D'INHIBITEURS DE LA 5-a-RÉDUCTASE ET UTILISATIONS DE CELLES-CI
EP3906019C0 (fr) Compositions pharmaceutiques de furosémide
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
IL289819A (en) Benzenesulfonamide derivatives and uses thereof
EP3817750A4 (fr) Compositions d'associations de cannabidiol
EP3846793A4 (fr) Inhibiteurs d'eif4e et leurs utilisations
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
EP3730138A4 (fr) Médicament comprenant une combinaison de sepetaprost et d'inhibiteur de la rho-kinase
MA54222A (fr) Combinaison d'un inhibiteur de mcl-1 et de midostaurine, utilisations et compositions pharmaceutiques associées
MA45718A (fr) Combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1, utilisations et compositions pharmaceutiques associées
EP3773613A4 (fr) Compositions pharmaceutiques contenant des polyrotaxanes